RxDoctor Payments DataLook up a doctor →

Sandip Vasavada, MD

Urology · Cleveland, OHNPI 1356306328

Payments from drug & device makers

$512,097in general payments, 2019–2025

Across 555 payments — averaging $922.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$211K
  • Medtronic$199K
  • Checkpoint Surgical, Inc$38K
  • Bluewind Medical$24K
  • Astellas Pharma Inc$21K
  • Purdue Pharma L.p.$7K
  • plus $12K from 16 others

What the payments were for

  • Consulting fees$24,5919%
  • Speaking & faculty fees$159,61061%
  • Grants$1210%
  • Travel & lodging$59,66723%
  • Food & beverage$18,7557%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$512,097 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$96,888
Medicare patients
343
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron154$83,413
GemtesaVibegron86$52,474
Trospium Chloride ErTrospium Chloride81$7,978
Estradiol94$5,508
Methenamine Hippurate39$3,854
Trospium Chloride94$3,705
Cephalexin51$374
Oxybutynin Chloride ErOxybutynin Chloride31$369
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$230
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim20$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$83$83,413154 claims
Sumitomo Pharma America, Inc.Gemtesa$268$52,47486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.

Other urology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →